| ¿µ¹® | IDDM(Insulin-Dependent Diabetes Mellitus) | ÇÑ±Û | Àν¶¸°ÀÇÁ¸´ç´¢º´ |
|---|---|---|---|
| ¼³¸í | IDDMÀº ´ç´¢º´ÀÇ Ä¡·á¿¡ ¹Ýµå½Ã Àν¶¸°ÀÌ ÇÊ¿äÇÑ °æ¿ì¸¦ ¸»ÇÑ´Ù. ÁÖ·Î ¿øÀÎÀÌ ÀÌÀÚ¿¡ ÀÖ´Â Àν¶¸°À» ºÐºñÇÏ´Â ¼¼Æ÷ÀÇ ÆÄ±«À̸ç ÀÌ·Î ÀÎÇØ¼ ´ç´¢º´ÀÇ Ä¡·áÁ¦·Î ¾²ÀÌ´Â Àν¶¸°ÀÇ ºÐºñ¸¦ ÃËÁøÇÏ´Â ¾à¹°ÀÌ ÀÌ IDDM¿¡¼´Â ¾²ÀÏ ¼ö°¡ ¾ø°í ¿ÀÁ÷ Àν¶¸°¸¸ÀÌ Ä¡·áÁ¦·Î ¾µ ¼ö°¡ ÀÖ´Ù. ÀüÇüÀûÀÎ Àν¶¸° ÀÇÁ¸Çü ´ç´¢º´Àº ¼Ò¾Æ¿¡¼ ÈçÈ÷ ¹ß»ýÇϰí Àν¶¸° ºÐºñ¼¼Æ÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ Àν¶¸° ºÐºñ´ÉÀº °ÅÀÇ ¾ø´Ù. |
||
| ¿µ¹® | thyroid hormone | ÇÑ±Û | °©»ó»ùÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ±¤ÀÇÀÇ °©»ó¼±È£¸£¸óÀº Ƽ·Ï½Å(thyroxine(T4)), »ï¿äµåƼ·Î´Ñ(triiodothyronine (T3)), Ƽ·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)ÀÇ 3°¡ÁöÁß Çϳª¸¦ ¸»Çϳª ´ë°³ÀÇ °æ¿ì ÇùÀÇÀÇ ¶æÀ¸·Î »ç¿ëµÇ¸ç ÀÌ °æ¿ì Ƽ·Ï½Å°ú »ï¿äµåƼ·Î´ÑÀ» ÁöĪÇÑ´Ù. °©»ó¼± È£¸£¸óÀº °ÅÀÇ ¸ðµç ¸ö¼¼Æ÷¿¡¼ÀÇ ¹ÙÅÁÁú´ë»ç¿¡ °ü¿©ÇÏ¿© ¿¡³ÊÁö»ý¼ºÀ» Áõ°¡½ÃŰ°í ¼ºÀå ¹ßÀ°À» ÃËÁøÇÑ´Ù. À̰ÍÀº ³úÇϼöü¿¡¼ ºÐºñµÇ´Â °©»ó»ù ÀÚ±ØÈ£¸£¸ó¿¡ ÀÇÇØ ÇÕ¼º ¹× ºÐºñ°¡ ÃËÁøµÈ´Ù. ¼·ÃëÇÏ¿© ü³»¿¡ µé¾î¿Â ¿ä¿Àµå°¡ ´Éµ¿¿î¹Ý¿¡ ÀÇÇØ °©»ó»ù¼¼Æ÷³»·Î µé¾î°¡ ¼¼Æ÷³»¿¡ ÀÖ´Â ´Ü¹éÁúÀÎ °©»ó»ù ±Û·Îºí¸°°ú °áÇÕÇÏ¿© °©»ó»ùÈ£¸£¸óÀ¸·Î ÇÕ¼ºµÈ´Ù. ¿ä¿Àµå°¡ 3ºÐÀÚ °áÇÕÇÑ °ÍÀ» T3, 4ºÐÀÚ °áÇÕÇÑ °ÍÀ» T4¶ó ºÎ¸§. ºÐºñµÇ´Â °©»ó¼± È£¸£¸óÁß 90%ÀÌ»óÀÌ T4ÀÌ´Ù. Ç÷ÁßÀ¸·Î ºÐºñµÈ °©»ó»ùÈ£¸£¸óÀº Ç÷Áß ´Ü¹éÁú°ú °áÇÕÇϴµ¥ ´ëºÎºÐÀº Ƽ·Ð½Å°áÇÕ±Û·Îºí¸°°ú °áÇÕÇϸç ÀϺδ ¾ËºÎ¹Î°ú °áÇÕÇÑ´Ù. Àü¹ÝÀûÀÎ ´ë»çÀ²À» ÃËÁø½ÃŰ¸ç ¾î¸°ÀÌ¿¡¼´Â ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ƯÈ÷ ¾î¸°ÀÌ¿¡¼ ¸ô´Ü¹éÁú ÇÕ¼ºÀ» ÃËÁøÇÏ¸ç ³úÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ±â´ÉÀ» ÇÔÀ¸·Î½á, ¼±Ãµ¼º °©»ó»ùÀúÇÏÁõ(cretinism)À» Á¶±â ¹ß°ßÇÏ¿© Ä¡·áÇÏÁö ¸øÇϸé Á¤½ÅÁöü°¡ À¯¹ßµÈ´Ù. °©»ó»ù°ú´ÙÁõÀÇ Áõ»óÀº ü³» ´ë»ç°¡ Ç×ÁøµÇ¾î ½Ä¿åÀÌ Áõ°¡Çϳª üÁßÀÌ °¨¼ÒÇÏ°í ½ÉÀå¹Úµ¿¼ö°¡ Áõ°¡ÇÏ°í ´õÀ§¸¦ ÂüÁö ¸øÇϸç, °©»ó»ù±â´ÉÀúÇÏÁõÀÇ Áõ»óÀº À§¿Í ¹Ý´ë·Î ½Ä¿åÀÌ °¨¼ÒÇϰí üÁßÀÌ Áõ°¡ÇÏ¸ç ½ÉÀå¹Úµ¿¼ö°¡ °¨¼ÒÇϰí ÃßÀ§¸¦ ÂüÁö ¸øÇϸç ÇǺο¡ ´Ü¹éÁúÀÌ ÃàÀûµÇ¾î Á¡¾×ºÎÁ¾ÀÌ À¯¹ßµÈ´Ù. |
||
| ¿µ¹® | adrenocorticotropic hormone | ÇÑ±Û | ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ³úÇϼöü Àü¿±¿¡¼ ºÐºñµÇ¾î ºÎ½Å°ÑÁúÀ» ÀÚ±ØÇÏ´Â ´Ü¹é¼º È£¸£¸ó. ÇϼöüÀü¿°¿¡¼ ¸¸µé¾îÁ® ºÐºñµÇ´Â È£¸£¸óÀÌ´Ù. ºÎ½Å°ÑÁúÀÚ±Ø ÀÛ¿ëÀÌ ÀÖÀ¸¸ç ºÎ½Å°ÑÁúÁú¼¼Æ÷ÀÇ °æ¿ì¿¡ ½ºÅ×·ÎÀ̵åÈ£¸£¸ó »ýÇÕ¼ºÀÇ Á¶Àý´Ü°èÀÎ ÄÝ·¹½ºÅ׷ѷκÎÅÍÀÇ ÇÁ·¹±×³×·Ñ·Ð»ý¼ºÀ» ÃËÁøÇÑ´Ù. °áÁ¤±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵忡 ÀÇÇØ ¹Ý´ëÀÇ µÇ¸ÔÀÓÁ¶Á¤À» ¹Þ´Â´Ù. ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵åÀÇ ÇϼöüÀü¿±¿¡ ´ëÇÑ Á÷Á¢ÀÛ¿ë°ú ½Ã»óÇϺÎÀÇ ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó ¹æÃâÈ£¸£¸óÀ» ¸Åü·Î ÇÑ °£Á¢ÀÛ¿ëÀÌ ÀÖ´Ù. ¿©·¯ Á¾·ùÀÇ Á¤½ÅÀû À°Ã¼Àû ½ºÆ®·¹½º¿¡ ÀÇÇØ ºÐºñ°¡ ÀڱصȴÙ. |
||
| ¿µ¹® | growth hormone | ÇÑ±Û | ¼ºÀåÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ³úÇϼöü Àü¿±¿¡¼ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀÚ±ØµÇ¸ç ¼Ò¸¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½Ã۸ç ƯÈ÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇÌµÇ¸é ¼ºÀåºÎÁøÀÌ ¿Â´Ù. |
||
| TD | tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus... |
|---|---|
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| BT | base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin... |
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
| TNM | primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas... |
| HD | Hormone-dependent |
|---|---|
| Gn-RH | gonadotropic hormone-releasing hormone |
| GH-RH | Growth Hormone Releasing Hormone |
| GHRH | Growth hormone (GH)-releasing hormone |
| GH-RIH | Growth hormone release inhibiting hormone |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| neoplasms, hormone-dependent | Certain tumours that 1) arise in organs that are normally dependent on specific hormones and 2) are stimulated or caused to regress by manipulation of the endocrine environment. (12 Dec 1998) |
| receptors, pituitary hormone-regulating hormone | Cell surface receptors that bind the hypothalamic hormones regulating pituitary cell differentiation, proliferation, and hormone synthesis and release, including the pituitary-releasing and release-inhibiting hormones. The pituitary hormone-regulating hormones are also released by cells other than hypothalamic neurons, and their receptors also occur on non-pituitary cells, especially brain neurons, where their role is less well understood. Receptors for dopamine, which is a prolactin release-inhibiting hormone as well as a common neurotransmitter, are not included here. (12 Dec 1998) |
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| growth hormone-regulating hormone | <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin). (18 Nov 1997) |
| growth hormone-releasing hormone | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| hormones, hormone substitutes, and hormone antagonists | A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. (12 Dec 1998) |
| follicle-stimulating hormone-releasing hormone | A decapeptide of hypothalamic origin capable of accelerating pituitary secretion of follitropin. Synonym: follicle-stimulating hormone-releasing factor, follicle-stimulating hormone-releasing hormone. Origin: follicle-stimulating hormone + L. Libero, to free, + -in (05 Mar 2000) |
| luteinizing hormone/follicle-stimulating hormone-releasing factor | gonadotrophin-releasing hormone |
| luteinizing hormone-releasing hormone | A hormone that controls sex hormones in men and women. Also called lhrh. (12 Dec 1998) |
| aid to families with dependent children | Financial assistance provided by the government to indigent families with dependent children who meet certain requirements as defined by the social security act, title IV, in the u.s. (12 Dec 1998) |
| androgen-dependent secretory protease | <enzyme> Glycoprotein from dog prostate; hydrolyzes arginine and lysine-containing amide and ester protease substrates Registry number: EC 3.4.99.- Synonym: ads-protease (26 Jun 1999) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|